Valuation: Immatics N.V.

Market Cap 914M 824M 761M 688M 1.3B 85.77B 1.33B 9.13B 3.64B 45.93B 3.43B 3.36B 146B P/E 2026 *
-3.19x
P/E 2027 * -3.27x
Enterprise Value 819M 738M 682M 616M 1.17B 76.77B 1.19B 8.17B 3.26B 41.12B 3.07B 3.01B 131B EV / Sales 2026 *
22.8x
EV / Sales 2027 * 18.1x
Free-Float
76.68%
Yield 2026 *
-
Yield 2027 * -
1 day+4.21%
1 week-3.18%
Current month-7.08%
1 month-9.96%
3 months-31.38%
6 months-42.03%
Current year-36.29%
1 week 6.09
Extreme 6.09
6.81
1 month 6.09
Extreme 6.09
7.95
Current year 6.09
Extreme 6.09
11.94
1 year 6.09
Extreme 6.09
12.41
3 years 3.3
Extreme 3.3
13.77
5 years 3.3
Extreme 3.3
14
10 years 0
Extreme 0
18.42
Manager TitleAgeSince
Chief Executive Officer 51 2018-12-31
Director of Finance/CFO 57 2025-09-30
Chief Tech/Sci/R&D Officer - 2024-12-31
Director TitleAgeSince
Director/Board Member 51 2020-06-30
Chairman 70 2012-09-30
Director/Board Member 72 2020-06-30
Date Insider Type Main position Quantity % Market Cap. Importance
8/26/26
Perceptive Advisors LLC
BuyCompany 863,060 0.6436%
3/18/26 Other

Chief Financial Officer

350,000 0.2611%
3/18/26 Other

Head of Human Resources

211,000 0.1574%
Change 5-day change 1-year change 3-year change Capi.($)
+4.21%-3.18%-27.20%-28.98% 914M
-1.06%-0.07%+60.76%+68.61% 67.53B
+1.30%+7.41%+14.79%+92.69% 60.74B
+0.39%+0.30%+20.04%+98.33% 55.66B
-0.95%+11.17%+22.21%+110.93% 47.97B
-0.23%+4.07%+25.63%+40.08% 45.24B
-6.40%-9.51%+181.99%+816.79% 39.08B
+1.97%+3.50%+25.78%+50.98% 35.34B
-0.56%-0.48%+85.57%+65.40% 33.45B
+1.05%+9.77%-37.66%+408.42% 26.49B
Average -0.03%+1.21%+37.19%+172.33% 41B
Weighted average by Cap. -0.47%+1.63%+44.14%+168.70%

Financials

2026 *2027 *
Net sales 35.85M 32.31M 29.85M 26.99M 51.06M 3.36B 52.32M 358M 143M 1.8B 135M 132M 5.73B 37.68M 33.96M 31.37M 28.36M 53.66M 3.53B 54.98M 376M 150M 1.89B 141M 138M 6.02B
Net income -298M -269M -248M -224M -424M -27.94B -435M -2.97B -1.18B -14.96B -1.12B -1.09B -47.62B -319M -288M -266M -240M -455M -29.94B -466M -3.19B -1.27B -16.03B -1.2B -1.17B -51.02B
Net Debt -95.9M -86.43M -79.85M -72.19M -137M -8.99B -140M -957M -381M -4.82B -360M -352M -15.33B -231M -208M -193M -174M -329M -21.69B -337M -2.31B -920M -11.62B -868M -849M -36.97B
Projected Income Statement - Annual - Immatics N.V.
Logo Immatics N.V.
Immatics N.V. is a clinical-stage biopharmaceutical company. The Company is primarily engaged in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics.PRAME is a target expressed approximately 50 cancers. Its PRAME franchise includes approximately three product candidates, two therapeutic modalities and three combination therapies that target PRAME: anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy, IMA203CD8 PRAME cell therapy, IMA402 PRAME bispecific as monotherapy, in combination with immune checkpoint inhibitors, in combination with IMA401 MAGEA4/8 bispecific as well as anzu-cel in combination with Moderna’s PRAME mRNA designed to enhance cell therapy. The Company has approximately two technology platforms for target and T Cell Receptor (TCR) discovery.
Employees
704
Date Price Change Volume
26-11-11 $6.690 +4.21% 964,315
26-11-10 $6.420 -0.16% 1,221,137
26-11-09 $6.430 +1.10% 691,621
26-11-06 $6.360 +2.91% 1,063,382
26-11-05 $6.180 -10.56% 1,278,171
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Immatics N.V.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
6.690USD
Average target price
16.40USD
Spread / Average Target
+145.14%
  1. Stock Market
  2. Stocks
  3. IMTX Stock